knowledge -WSS

knowledge

author：entertainment 2025-10-02 22:30:13 - browse：83

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Solve the antibiotic resistance crisis with preventive drugs

leisure time

Wikipedia

WSS

Microsoft's Peter Lee: Generative AI could help doctors be more human

STAT Readout Newsletter: Today's biggest biotech updates

He's 19 months old and has one of the world’s rarest diseases

Immune cells and nerve overgrowth may explain recurring UTI pain

Florida health officials providing scant details on measles cases

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

focus

knowledge

hotspot

Jerome Adams on the need for new antivirals for Covid

$1 billion proposal to grow Boston, Massachusetts biotech

New air purifier tech could be key to improving indoor air quality

Ancient Greek ideas underpin modern concepts of pregnancy

Virginia high school admissions case could be legal follow

STAT Summit: Biotech founders on deal

New air purifier tech could be key to improving indoor air quality

Longer MASH drug regimen improved liver, Akero study finds

Duchenne breakthrough therapy leaves behind pioneering families

Beam Therapeutics to lay off 20% of its staff, re

entertainment

Harvard's David Sinclair gets blowback over aging

Researchers explore possible ties between long Covid, menopause

Longer MASH drug regimen improved liver, Akero study finds

The EU Joint Clinical Assessment needs to live up to its promise

UnitedHealth’s board chair also owns a personal investment firm

The EU Joint Clinical Assessment needs to live up to its promise

leisure time

leisure time

Wikipedia

focus